Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.

PURPOSE We studied the efficacy and safety of bortezomib (BOR) for treatment of multiple myeloma in comparison with thalidomide (THAL) by reference to adverse events, and searched for laboratory markers that could be used for prognostication of patients. METHODS Biochemical data of patients receiving BOR and THAL for treatment of multiple myeloma at the… CONTINUE READING